Article Text

Download PDFPDF
Improving first-line therapy of advanced ovarian cancer – the AGO Ovarian Cancer Study Group perspective
  1. A. Du Bois,
  2. J. Pfisterer,
  3. W. Meier and
  4. U. Wagner
  1. Address correspondence and reprint requests to: Andreas du Bois, Department Gynecology & Gynecologic Oncology, Dr Horst-Schmidt-Kliniken, Wiesbaden, Germany. Email: dubois.hsk-Wiesbaden{at}


This review displays the AGO Ovarian Cancer Study Group approach towards evaluation of improvement options in first-line therapy of advanced ovarian cancer. Prospectively randomized phase III trials evaluating the addition of newer drugs to standards carboplatin-paclitaxol (TC) as well as pilot trials evaluating new treatment modalities like anti-idiotype CA 125 antibodies or epidermal growth factor receptor (EGFR) modulation are presented.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.